EarningsQ2 2026 Earnings Report
DE:B0F Q2 2026 EPS Results
Actual EPS<€0.01
Consensus EPS€0.03
Beat/MissMissed by -€0.02
One Year Ago EPS>-€0.01
DE:B0F Q2 2026 Revenue Results
Actual Revenue€9.48M
Expected Revenue€8.62M
Beat/MissBeat by +€861.71K
YoY Revenue Growth+40.26%
Earnings Announcement Details
QuarterQ2 2026
Date08/21/2026
TimeBefore Open
Conference CallFriday, August 21, 2026
DE:B0F Upcoming Earnings
Paxman AB's next earnings date is estimated for November 20, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:B0F Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.Company Guidance
Record Group Sales and Strong YoY Growth
Group sales totaled just over SEK 105 million, the first time exceeding SEK 100 million, representing approximately 40% year-on-year growth.
Improved Profitability and EBITDA Contribution from Acquisition
Quarterly EBITDA was about SEK 14 million; the Dignitana acquisition contributed roughly SEK 5.2 million to EBITDA. Adjusted EBITDA margin was nearly 19% (18.5% reported), showing margin improvement year-over-year.
Significant Insurance-Based Billing (IBBM) Expansion
Insurance-based billing revenues grew 110%, driving utilization and recurring revenue via caps (1,326 caps sold through IBBM this quarter).
Strong U.S. Revenue Momentum
U.S. revenues for the group reached $7.1 million this quarter versus $4.0 million in the same quarter 2025, approximately +77.5% year-on-year growth.
Robust Order Book and Installations
56 systems were delivered in the quarter. Order book stands at 190 systems on order, with 80 of those in the U.S., indicating continued demand and future revenue potential.
Material Utilization Uplift Under IBBM
Utilization under IBBM materially exceeds self-pay: self-pay averages 3.1 patients per site (1.6 per system) versus IBBM averages of 8.6 patients per site (3.4 per system), demonstrating the revenue leverage from switching to IBBM.
Solid Cash Position
Available cash remains strong with SEK 105 million in the bank, and management notes a generally positive cash flow trend despite investments.
Integration and Stabilization of Dignitana
Post-acquisition stabilization underway with cross-company synergies, US activity investments and positive early momentum on utilization and IBBM adoption in Dignitana markets.
DE:B0F Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed